Quantum Ledger
Vol. III·Cohort Profile·Algorithmiq
Helsinki, Finland·Founded 2020·Private
Boulder · Colorado
Analyst note · Software / QEC

Algorithmiq Software / QEC

Most-funded quantum drug discovery software company — pivoting from generic chemistry to clinical pharma partnerships.

Most-funded quantum drug discovery software company — pivoting from generic chemistry to clinical pharma partnerships.

— Ledger Desk · analyst thesis

Bull case

▲ upside

$15M Series A 2023 + €10M extension; Roche, AstraZeneca research partnerships; published quantum-error-mitigation work that runs on IBM hardware. Sabrina Maniscalco (Helsinki) anchors the science. Strong position as IBM Quantum chemistry partner.

Bear case

▼ downside

Quantum chemistry advantage at scale is still 3–5 years away on real hardware; software-only companies have narrow moats once hardware vendors internalize chemistry stacks. Revenue not publicly disclosed.

A profile is a snapshot of an argument, not a verdict. The Ledger updates the score nightly; the thesis we revisit only when the facts change.

— analyst-note conventions